GlassScriptPhysician profile
Usha K Bulusu
NPI 1043202948
$30,104.50
in general payments reported to CMS, 2019-2025
29 companies · $26K in 2025
The $26K reported for 2025 was more than what 97% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $487 · 2020: $242 · 2021: $343 · 2022: $650 · 2023: $1,011 · 2024: $1,147 · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Food and Beverage: $5,432 · Travel and Lodging: $1,951.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $21,000.00 |
| Food and Beverage | $5,432.32 |
| Travel and Lodging | $1,950.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $24,856.23 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Alcon Vision LLC | $1,673.83 | 2019-2025 | Hydrus Microstent, Clareon, Clareon Panoptix Pro |
| Abbvie INC. | $634.77 | 2022-2025 | Durysta, Xen Glaucoma Treatment System, Alphagan P |
| Ocular Therapeutix, INC. | $375.56 | 2019-2025 | Dextenza |
| Sun Pharmaceutical Industries INC. | $329.38 | 2019-2025 | Cequa |
| Allergan, INC. | $257.09 | 2021-2022 | |
| Glaukos Corporation | $256.87 | 2019-2024 | Idose, Istent Trabecular Micro-Bypass System Model Is3 |
| Tarsus Pharmaceuticals, INC. | $231.27 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $216.20 | 2022-2025 | Vyzulta, Miebo, Zylet |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $197.10 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $188.11 | 2025 | Yutiq, Purified Cortrophin Gel, Iluvien |
| Aerie Pharmaceuticals, INC. | $165.79 | 2019-2020 | |
| Biotissue Holdings INC. | $127.92 | 2023-2025 | |
| New World Medical,INC. | $99.21 | 2019-2025 | Clearpath, Ahmed Glaucoma Valve, Kahook Dual Blade |
| Merz North America, INC. | $87.13 | 2023 | Xeomin |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $68.56 | 2020-2022 | |
| Harrow Eye, LLC | $56.81 | 2025 | Vevye, Iheezo |
| Oyster Point Pharma, INC. | $44.24 | 2023-2024 | Tyrvaya, Ryzumvi |
| Kala Pharmaceuticals, INC. | $41.98 | 2019-2020 | |
| Nova Eye, INC. | $25.79 | 2025 | |
| Surgical Specialties Corporation (US), INC. (Dba Corza Medical) | $24.31 | 2024 | |
| Rxsight INC | $23.06 | 2025 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Injector Cartridge |
| Lombart Brothers, INC. | $21.95 | 2019 | |
| Thea Pharma INC. | $19.85 | 2024 | Iyuzeh |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Rayner Intraocular Lenses Limited | $18.53 | 2025 | Omidria |
| Eyepoint US, INC. | $15.85 | 2019 | |
| Dompe US, INC. | $14.61 | 2021 | |
| Shire North American Group INC | $13.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Usha Bulusu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.